8-K: Syra Health Stockholders Elect Directors, Approve Charter Amendments

Syra Health Corp. stockholders approved all five director nominees, ratified its auditor, and passed two amendments related to Class B common stock at its Annual Meeting.

Summary

• Syra Health Corp. held its Annual Meeting of Stockholders on November 14, 2025.
• A quorum was established with 15,848,410 shares of common stock represented, including 600,000 shares of Class B common stock, each carrying 16.5 votes.
• All five director nominees—Priya Prasad, Dr. Vijayapal R. Reddy, Dr. Ketan Paranjape, Dr. Avutu S. Reddy, and Radhika Mereddy—were elected to serve until the 2026 Annual Meeting.
• The appointment of M&K CPAs, PLLC as the independent registered public accounting firm for the fiscal year ended December 31, 2025, was ratified with 14,955,596 votes For.
• An amendment to delete Article IV, Section 4.2.8(D) of the Amended and Restated Certificate of Incorporation, which allowed for automatic conversion of Class B Common Stock upon the death of a Class B stockholder, was approved with 8,917,010 votes For.
• An amendment to Section 4.2.8 of the Amended and Restated Certificate of Incorporation, allowing Class B shares to be transferred to immediate family members, heirs, successors, and assigns without conversion, was approved with 8,880,105 votes For.

Sentiment

Score: 7

Explanation: Stockholders approved all management-backed proposals, including director elections and key amendments to Class B common stock provisions, despite some opposition to the Class B changes. This indicates a generally positive outcome for the company's governance structure.

Positives

• All five director nominees were successfully elected, ensuring continuity in corporate leadership.
• The appointment of M&K CPAs, PLLC as the independent auditor was ratified, maintaining financial oversight and compliance.
• Stockholders approved amendments to the Certificate of Incorporation that provide greater flexibility and longevity for Class B common stock holders regarding transferability and conversion upon death.

Negatives

• A significant number of votes were cast 'Against' Proposal 3 (4,632,013 votes) and Proposal 4 (4,631,020 votes), indicating notable stockholder opposition to the proposed Class B common stock amendments.
• A substantial number of 'Broker Non Vote' shares (2,247,235) for the director elections and Class B amendments suggests a portion of shares were not voted on these discretionary matters.

Future Outlook

NA

Industry Context

NA

Corporate Governance

Stakeholder Impact

• Shareholders: All shareholders are impacted by the continuity of the board and the ratification of the auditor. Class B shareholders specifically benefit from the approved amendments regarding transferability and conversion upon death, which could affect their long-term control and estate planning.
• Management/Directors: The re-election of all five director nominees provides stability and continuity for the current management team and strategic direction.

Next Steps

• The elected directors will serve until the 2026 Annual Meeting of Stockholders or until their successors are duly elected and qualified.

Key Dates

Recommendation

The filing details the outcomes of the Annual Meeting of Stockholders, including the election of directors and ratification of the auditor, which are standard corporate governance events. While amendments to Class B common stock transferability were approved, these changes primarily affect internal control structures rather than immediate operational or financial performance. There is no new financial data, strategic shifts, or material risks disclosed that would fundamentally alter the investment outlook, thus a 'hold' recommendation is appropriate as investors await further operational or financial updates.

Keywords

Syra Health, Annual Meeting, Stockholder Vote, Director Election, Auditor Ratification, Class B Common Stock, Corporate Governance, SEC Filing, 8-K